Literature DB >> 2908235

A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity.

E Goodall1, C Oxtoby, R Richards, G Watkinson, D Brown, T Silverstone.   

Abstract

Twenty-nine overweight schizophrenic patients maintained on depot neuroleptic injections who wished to lose weight took part in a double-blind, placebo-controlled trial of 30 mg D-fenfluramine. All subjects received dietary advice. Sixteen patients completed the 12-week trial. Rate of weight loss was significantly greater in those taking D-fenfluramine. Side-effects were reported, but no deterioration in mental state was noted.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2908235     DOI： 10.1192/bjp.153.2.208

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN： 0007-1250            Impact factor:   9.319


  17 in total

Review 1.  Management of antipsychotic-related weight gain.

Authors:  Lawrence Maayan; Christoph U Correll
Journal:  Expert Rev Neurother       Date:  2010-07       Impact factor: 4.618

Review 2.  Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.

Authors:  Lawrence Maayan; Julia Vakhrusheva; Christoph U Correll
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

Review 3.  Interventions to reduce weight gain in schizophrenia.

Authors:  G Faulkner; T Cohn; G Remington
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

4.  From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.

Authors:  Sangwon F Kim; Alex S Huang; Adele M Snowman; Cory Teuscher; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

5.  Interventions for the metabolic syndrome in schizophrenia: a review.

Authors:  Evangelos Papanastasiou
Journal:  Ther Adv Endocrinol Metab       Date:  2012-10       Impact factor: 3.565

Review 6.  Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis.

Authors:  Yuya Mizuno; Takefumi Suzuki; Atsuo Nakagawa; Kazunari Yoshida; Masaru Mimura; Walter Wolfgang Fleischhacker; Hiroyuki Uchida
Journal:  Schizophr Bull       Date:  2014-03-17       Impact factor: 9.306

Review 7.  Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis.

Authors:  Salvatore Gentile
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

8.  Hypothalamic Ahi1 mediates feeding behavior through interaction with 5-HT2C receptor.

Authors:  Hao Wang; Zhenbo Huang; Liansha Huang; Shaona Niu; Xiurong Rao; Jing Xu; Hui Kong; Jianzhong Yang; Chuan Yang; Donghai Wu; Shihua Li; Xiao-Jiang Li; Tonghua Liu; Guoqing Sheng
Journal:  J Biol Chem       Date:  2011-11-28       Impact factor: 5.157

Review 9.  Pitfalls and problems of the long term use of neuroleptic drugs in schizophrenia.

Authors:  M F Bristow; S R Hirsch
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

Review 10.  Appetite suppressants. A review.

Authors:  T Silverstone
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.